Novo Nordisk A/S ADR Company Profile | StatInvestor

Health Care & Life Sciences » Pharmaceuticals | Novo Nordisk A/S

Novo Nordisk A/S

Novo Nordisk A/S ADR
Stock Exchange	New York Stock Exchange
EPS	$2.47
Market Cap	$91.39 B
Shares Outstanding	1.86 B
Public Float	1.91 B

Novo Nordisk A/S ADR
Stock Exchange	Mexican Stock Exchange
EPS	-
Market Cap	-
Shares Outstanding	2.41 B
Public Float	-

Novo Nordisk A/S Series B
Stock Exchange	Copenhagen Stock Exchange
EPS	DKK15.88
Market Cap	DKK795.17 B
Shares Outstanding	1.86 B
Public Float	1.7 B

Novo Nordisk A/S Series B
Stock Exchange	Xetra Stock Exchange
EPS	EUR2.13
Market Cap	EUR106.22 B
Shares Outstanding	1.91 B
Public Float	-

Novo Nordisk A/S Series B
Stock Exchange	London Stock Exchange
EPS	DKK15.88
Market Cap	DKK794.7 B
Shares Outstanding	1.91 B
Public Float	-

Novo Nordisk A/S Series B
Stock Exchange	Other OTC
EPS	$2.47
Market Cap	$120.06 B
Shares Outstanding	1.91 B
Public Float	-

Novo Nordisk A/S ADR
Stock Exchange	Xetra Stock Exchange
EPS	EUR2.15
Market Cap	EUR101.83 B
Shares Outstanding	2.41 B
Public Float	-

Novo Nordisk A/S Series B
Stock Exchange	SIX Swiss Exchange
EPS	-
Market Cap	-
Shares Outstanding	1.91 B
Public Float	-

Profile

Address	Novo Allé Bagsværd CR 2880 Denmark
Employees	-
Website	http://www.novonordisk.com
Updated	07/08/2019
Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. It operates through the following business segments: Diabetes & Obesity Care, and Biopharmaceuticals. The Diabetes & Obesity Care segment covers products for insulin; GLP-1 and related delivery systems; oral antidiabetic products; and obesity.

Financials

Helge Lund

Chairman

Marcus Schindler

Director, SVP-External Innovation & Strategy